JonesResearch initiated coverage of ArriVent Biopharma (AVBP) with a Buy rating and $40 price target ArriVent is the leading oral EGFR TKI in front-line atypical EGFR mutated non-small cell lung cancer – a monotherapy regimen against EGFR exon 20 insertion and PACC mutations, the analyst tells investors in a research note. The firm expects pivotal Phase 3 data from EGFR ex20ins mutated lung cancer in the second half of 2025, and potential FDA approval within 12-15 months.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVBP:
- ArriVent Biopharma price target raised to $40 from $39 at H.C. Wainwright
- ArriVent BioPharma Advances Cancer Pipeline in Q1 2025
- ArriVent BioPharma: Promising Clinical Developments and Strategic Advancements Justify Buy Rating
- ArriVent Biopharma reports Q1 EPS ($1.90), consensus (69c)
- ArriVent Biopharma sees cash, equivalents funding operations into 2H26